Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of PSO17CSF in patients with motor neuron disease
jRCT2011220046Phase 2Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Dec 2023
- Countries
- 1
01
Overview
Phase 2, open-label trial of PSO17CSF in motor neuron disease (MND) (3 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Safety. Started Dec 2023; status: active, not recruiting.
02
Drugs
PSO17CSF
03
Conditions
motor neuron disease (MND)
Beyond the preview
Go deeper on jRCT2011220046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011220046.